Xeljanz Doesn't Improve Radiographic Progression In Psoriatic Arthritis. Does It Matter?
Pfizer's JAK inhibitor met its co-primary efficacy endpoints, but US FDA still wants discussion of lack of impact on radiographic progression.
Pfizer's JAK inhibitor met its co-primary efficacy endpoints, but US FDA still wants discussion of lack of impact on radiographic progression.